Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Prostate Cancer

Free Subscription 16.09.2019 2 Anticancer Res 2 BJU Int 1 BMC Cancer 1 BMC Urol 1 Br J Cancer 1 Cancer 1 Cancer Lett 1 Cancer Res 2 Clin Cancer Res 1 Eur Radiol 3 Eur Urol 1 Int J Urol 1 J Clin Oncol 3 J Urol 1 Lancet Oncol 2 Nat Rev Urol 1 PLoS One 6 Prostate 1 Radiology 1 Urology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Anticancer Res

1. TAKAGI H, Ii H, Kageyama S, Hanada E, et al
   Blockade of gamma-Glutamylcyclotransferase Enhances Docetaxel Growth Inhibition of Prostate Cancer Cells.
   Anticancer Res. 2019;39:4811-4816.
   PubMed     Text format     Abstract available
   
   
2. ZAMAGNI A, Buwenge M, Macchia G, Siepe G, et al
   Accelerated Middle Half Body Radiotherapy in Bone Metastases from Prostate Cancer: A Phase I Study (SHARON Project).
   Anticancer Res. 2019;39:5065-5069.
   PubMed     Text format     Abstract available
   
   

   
   BJU Int

3. ONG WL, Koh TL, Lim Joon D, Chao M, et al
   Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literatur
   BJU Int. 2019 Sep 11. doi: 10.1111/bju.14886.
   PubMed     Text format     Abstract available
   
   
4. GNANAPRAGASAM VJ
   Informing informed decision making in Primary Prostate Cancer treatment selection.
   BJU Int. 2019 Sep 12. doi: 10.1111/bju.14910.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

5. MARVASO G, Ciardo D, Corrao G, Gandini S, et al
   Radioablation +/- hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159).
   BMC Cancer. 2019;19:903.
   PubMed     Text format     Abstract available
   
   

   
   BMC Urol

6. OEHLER C, Zimmermann M, Adam L, Curschmann J, et al
   Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience.
   BMC Urol. 2019;19:84.
   PubMed     Text format     Abstract available
   
   

   
   Br J Cancer

7. THURTLE DR, Jenkins V, Pharoah PD, Gnanapragasam VJ, et al
   Understanding of prognosis in non-metastatic prostate cancer: a randomised comparative study of clinician estimates measured against the PREDICT prostate prognostic model.
   Br J Cancer. 2019 Sep 16. pii: 10.1038/s41416-019-0569.
   PubMed     Text format     Abstract available
   
   

   
   Cancer

8. SANTOS PMG, Barsky AR, Hwang WT, Deville C, et al
   Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting.
   Cancer. 2019 Sep 10. doi: 10.1002/cncr.32457.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Lett

9. LIANG Z, Cao J, Tian L, Shen Y, et al
   Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-alpha/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer.
   Cancer Lett. 2019 Sep 6. pii: S0304-3835(19)30465.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Res

10. TAYLOR RA, Watt MJ
    Unsuspected Protumorigenic Signaling Role for the Oncometabolite GABA in Advanced Prostate Cancer.
    Cancer Res. 2019;79:4580-4581.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

11. FENDLER WP, Weber M, Iravani A, Hofman MS, et al
    Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2019 Sep 11. pii: 1078-0432.CCR-19-1050.
    PubMed     Text format     Abstract available
    
    
12. SPRATT DE, Alshalalfa M, Fishbane N, Weiner AB, et al
    Transcriptomic heterogeneity of androgen receptor (AR) activity defines a de novo low AR-active subclass in treatment naive primary prostate cancer.
    Clin Cancer Res. 2019 Sep 12. pii: 1078-0432.CCR-19-1587.
    PubMed     Text format     Abstract available
    
    

    
    Eur Radiol

13. ANTONELLI M, Johnston EW, Dikaios N, Cheung KK, et al
    Correction to: Machine learning classifiers can predict Gleason pattern 4 prostate cancer with greater accuracy than experienced radiologists.
    Eur Radiol. 2019 Sep 10. pii: 10.1007/s00330-019-06429.
    PubMed     Text format     Abstract available
    
    

    
    Eur Urol

14. ALCARAZ A
    Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer.
    Eur Urol. 2019 Sep 12. pii: S0302-2838(19)30683.
    PubMed     Text format    
    
    
15. NYBERG T, Frost D, Barrowdale D, Evans DG, et al
    Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
    Eur Urol. 2019 Sep 5. pii: S0302-2838(19)30675.
    PubMed     Text format     Abstract available
    
    
16. CULP MB, Soerjomataram I, Efstathiou JA, Bray F, et al
    Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates.
    Eur Urol. 2019 Sep 4. pii: S0302-2838(19)30619.
    PubMed     Text format     Abstract available
    
    

    
    Int J Urol

17. KAWAMURA H, Kubo N, Sato H, Miyasaka Y, et al
    Quality of life in prostate cancer patients receiving particle radiotherapy: A review of the literature.
    Int J Urol. 2019 Sep 11. doi: 10.1111/iju.14102.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

18. VANDERWEELE DJ, Antonarakis ES, Carducci MA, Dreicer R, et al
    Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy.
    J Clin Oncol. 2019 Sep 10:JCO1901595. doi: 10.1200/JCO.19.01595.
    PubMed     Text format    
    
    

    
    J Urol

19. RESNICK MJ
    Re: Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial.
    J Urol. 2019 Sep 13:101097JU0000000000000550. doi: 10.1097/JU.0000000000000550.
    PubMed     Text format    
    
    
20. ATALA A
    Re: Communication of Prostate Cancer Cells with Bone Cells via Extracellular Vesicle RNA; a Potential Mechanism of Metastasis.
    J Urol. 2019 Sep 12:10109701JU0000585156807772.
    PubMed     Text format    
    
    
21. WEINSTOCK C, Suzman D, Kluetz P, Baxley J, et al
    Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: FDA Oncology Center of Excellence Public Workshop.
    J Urol. 2019 Sep 10:101097JU0000000000000532. doi: 10.1097/JU.0000000000000532.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Oncol

22. ANTONARAKIS ES
    Targeting lineage plasticity in prostate cancer.
    Lancet Oncol. 2019 Sep 9. pii: S1470-2045(19)30497.
    PubMed     Text format    
    
    

    
    Nat Rev Urol

23. STONE L
    Three times a charm for the third Prostate Cancer summit in Hamburg.
    Nat Rev Urol. 2019 Sep 12. pii: 10.1038/s41585-019-0235.
    PubMed     Text format    
    
    
24. BADAL S, Campbell KS, Valentine H, Ragin C, et al
    The need for cell lines from diverse ethnic backgrounds for prostate cancer research.
    Nat Rev Urol. 2019 Sep 13. pii: 10.1038/s41585-019-0234.
    PubMed     Text format    
    
    

    
    PLoS One

25. JEON JM, Kwon OK, Na AY, Sung EJ, et al
    Correction: Secretome profiling of PC3/nKR cells, a novel highly migrating prostate cancer subline derived from PC3 cells.
    PLoS One. 2019;14:e0222693.
    PubMed     Text format     Abstract available
    
    

    
    Prostate

26. LOW JY, Sirajuddin P, Moubarek M, Agarwal S, et al
    Effective targeting of RNA polymerase I in treatment-resistant prostate cancer.
    Prostate. 2019 Sep 16. doi: 10.1002/pros.23909.
    PubMed     Text format     Abstract available
    
    
27. ZHU Z, Hong Y, Zhang F, An L, et al
    Knockdown of COPS3 inhibits the progress of prostate cancer through reducing phosphorylated p38 MAPK expression and impairs the epithelial-mesenchymal transition process.
    Prostate. 2019 Sep 11. doi: 10.1002/pros.23907.
    PubMed     Text format     Abstract available
    
    
28. VELLKY JE, Bauman TM, Ricke EA, Huang W, et al
    Incidence of androgen receptor and androgen receptor variant 7 coexpression in prostate cancer.
    Prostate. 2019 Sep 10. doi: 10.1002/pros.23906.
    PubMed     Text format     Abstract available
    
    
29. XU Y, Huang D, Wu Y, Ye D, et al
    Family history is significantly associated with prostate cancer and its early onset in Chinese population.
    Prostate. 2019 Sep 9. doi: 10.1002/pros.23900.
    PubMed     Text format     Abstract available
    
    
30. GEORGE DJ, Halabi S, Healy P, Barak I, et al
    Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
    Prostate. 2019 Sep 9. doi: 10.1002/pros.23899.
    PubMed     Text format     Abstract available
    
    
31. ROBERTO D, Selvarajah S, Park PC, Berman D, et al
    Functional validation of metabolic genes that distinguish Gleason 3 from Gleason 4 prostate cancer foci.
    Prostate. 2019 Sep 10. doi: 10.1002/pros.23903.
    PubMed     Text format     Abstract available
    
    

    
    Radiology

32. MUEHLEMATTER UJ, Burger IA, Becker AS, Schawkat K, et al
    Diagnostic Accuracy of Multiparametric MRI versus (68)Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer.
    Radiology. 2019 Sep 10:190687. doi: 10.1148/radiol.2019190687.
    PubMed     Text format     Abstract available
    
    

    
    Urology

33. GRONDHUIS PALACIOS LA, van Zanten P, den Ouden MEM, Krouwel EM, et al
    Discrepancy between Expectations and Experiences after Prostate Cancer Treatment: A Dutch Multicenter Study.
    Urology. 2019 Sep 5. pii: S0090-4295(19)30796.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: